#$ARWR Tweets

StockTwits

Arrowhead at a glance: (click here to show/hide)

Arrowhead - Press Releases and SEC Filings	Chart:	Clinical Trials:	Goals for 2016:	C. Anzalone on CNBC:	What is RNAi ?

widget @ surfing-waves.com

About Arrowhead Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics.
Targeting Innovation
Arrowhead Pharmaceuticals develops novel drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. Arrowhead’s most advanced drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Arrowhead’s second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Lead Products
ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. It is the first clinical-stage drug candidate from Arrowhead’s Dynamic Polyconjugate® delivery platform. It is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins with the goal of achieving a functional cure for HBV.

ARC-AAT is a novel unlocked nucleobase analog (UNA)-containing RNAi-based therapeutic for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare genetic disease that can severely damage the liver and lungs of affected individuals. The goal of treatment with ARC-AAT is to reduce the production of the mutant Z-AAT protein to prevent and potentially reverse accumulation-related liver injury and fibrosis.

The companys pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates.

Platform Delivery Technology
The Dynamic Polyconjugate (DPC®) platform is an RNAi delivery system that has been demonstrated to preferentially deliver to hepatocytes, induce efficient endosomal escape, promote high levels of gene knockdown in multiple animal models, and appears to be well tolerated using a variety of RNAi trigger molecules. It is a modular system that can be optimized on a target-by-target basis and may be targeted in the future to address multiple organ systems and cell types.

Pipeline Development Strategy
Arrowhead’s internal drug pipeline is intended to drive value directly through the clinical development of novel therapeutics and to provide proof of concept for our platform technologies. In addition to our two lead product candidates, ARC-520 and ARC-AAT, we intend to nominate additional clinical candidates that utilize the DPC delivery system. Our core areas of focus for expanding our internal pipeline of RNAi therapeutics are: (1) develop intravenous (IV) administered liver-targeted candidates; (2) develop subcutaneously administered liver-targeted candidates; and (3) explore extra-hepatic targets, including oncology.

To learn more about Arrowhead visit the company's website at: http://arrowheadpharma.com/

Reply

Mispricing

« Prev
1
Next »

holdencf

ARWR New Member

Posts: 32

Registered: Nov 27, 2015 14:14:59 GMT -5

Mispricing Sept 6, 2016 16:34:09 GMT -5 buffettlike likes this

Quote

Post by holdencf on Sept 6, 2016 16:34:09 GMT -5

For all of you who don't think the market misprices assets, read the attached. Good read. Theranos had been valued at $9Bn (I assume valuation at last capital raise). Now (according to Forbes or Fortune) worthless.

www.cnbc.com/2016/09/06/only-elizabeth-holmes-knew-it-all-at-once-lauded-theranos-vfs-nick-bilton.html

[Go to Top] [Go to Bottom]

buffettlike ARWR New Member Posts: 22 Registered: Mar 7, 2016 16:47:58 GMT -5	Mispricing Sept 6, 2016 17:21:34 GMT -5 Quote Select Post Deselect Post Link to Post Member Give Gift Back to Top Post by buffettlike on Sept 6, 2016 17:21:34 GMT -5 Take a look at Theranos board: fortune.com/2015/10/15/theranos-board-leadership/
	[Go to Top] [Go to Bottom]

holdencf

ARWR New Member

Posts: 32

Registered: Nov 27, 2015 14:14:59 GMT -5

Mispricing Sept 6, 2016 19:30:26 GMT -5 grandcaddy, colvol46, and 2 more like this

Quote

Post by holdencf on Sept 6, 2016 19:30:26 GMT -5

Since that time multiple BOD members have departed. It is not the way I would construct a Board. Maybe one or two "Big Names." But that's not the kind of BOD this company needs right now. At best they get useless face time from most of them. They need 3 or four medical device experts, specifically lab detection equipment specialists and maybe a worlds hematologist. With the exception of McKinny ARWR's BOD is well-constructed. I would add a strong senior buy side person from NY in place of McKinny. I wouls ask Baker Bros to source someone. Then leave a slot open for a person with strong commercial banking ties for the next stage of company development.

[Go to Top] [Go to Bottom]

ARWR New Member

Posts: 22

Registered: Mar 7, 2016 16:47:58 GMT -5

Mispricing Sept 7, 2016 22:15:07 GMT -5 qbeing1010 and irelandguy like this

Quote

Post by buffettlike on Sept 7, 2016 22:15:07 GMT -5

Article states Charles P. McKenney past away last August. ARWR web site only list 5 board members, maybe Felix Baker can fill a seat on the board.

www.law360.com/articles/743110/arrowhead-can-t-ditch-investor-suit-over-hep-b-drug-trial

[Go to Top] [Go to Bottom]

Last Edit: Sept 7, 2016 22:18:49 GMT -5 by buffettlike

Latest videos from CNBC: